Clasp Therapeutics, a biotechnology company pioneering precision immuno-oncology through next-generation T cell engagers (TCEs), has announced its official launch this month, backed by $150 million in Series A financing. Clasp seeks to address the unmet needs of cancer patients who do not respond to existing treatments. The firm is backed by Third Rock Ventures, Novo Holdings, and Catalio Capital; with participation from Vivo Capital, Cure Ventures, Blackbird BioVentures, Pictet Alternative Advisors, American Cancer Society's Bright Edge and Alexandria Venture Investments.